These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37575233)

  • 1. Berberine-containing natural-medicine with boiled peanut-OIT induces sustained peanut-tolerance associated with distinct microbiota signature.
    Srivastava K; Cao M; Fidan O; Shi Y; Yang N; Nowak-Wegrzyn A; Miao M; Zhan J; Sampson HA; Li XM
    Front Immunol; 2023; 14():1174907. PubMed ID: 37575233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy.
    Srivastava KD; Siefert A; Fahmy TM; Caplan MJ; Li XM; Sampson HA
    J Allergy Clin Immunol; 2016 Aug; 138(2):536-543.e4. PubMed ID: 27130858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of pathologic immunoglobulin E in food allergy by EBF-2 and active compound berberine associated with immunometabolism regulation.
    Yang N; Maskey AR; Srivastava K; Kim M; Wang Z; Musa I; Shi Y; Gong Y; Fidan O; Wang J; Dunkin D; Chung D; Zhan J; Miao M; Sampson HA; Li XM
    Front Immunol; 2023; 14():1081121. PubMed ID: 36825019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-FAHF-2 plus oral immunotherapy (OIT) is safer and more effective than OIT alone in a murine model of concurrent peanut/tree nut allergy.
    Srivastava KD; Song Y; Yang N; Liu C; Goldberg IE; Nowak-Węgrzyn A; Sampson HA; Li XM
    Clin Exp Allergy; 2017 Aug; 47(8):1038-1049. PubMed ID: 28397379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allergen-specific oral immunotherapy for peanut allergy.
    Nurmatov U; Venderbosch I; Devereux G; Simons FE; Sheikh A
    Cochrane Database Syst Rev; 2012 Sep; (9):CD009014. PubMed ID: 22972130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral immunotherapy using boiled peanuts for treating peanut allergy: An open-label, single-arm trial.
    Grzeskowiak LE; Tao B; Aliakbari K; Chegeni N; Morris S; Chataway T
    Clin Exp Allergy; 2023 Mar; 53(3):327-336. PubMed ID: 36628520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained silencing peanut allergy by xanthopurpurin is associated with suppression of peripheral and bone marrow IgE-producing B cell.
    Yang N; Srivastava K; Chen Y; Li H; Maskey A; Yoo P; Liu X; Tiwari RK; Geliebter J; Nowak-Wegrzyn A; Zhan J; Li XM
    Front Immunol; 2024; 15():1299484. PubMed ID: 38380329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy.
    Dreskin SC; Germinaro M; Reinhold D; Chen X; Vickery BP; Kulis M; Burks AW; Negi SS; Braun W; Chambliss JM; Eglite S; McNulty CMG
    Pediatr Allergy Immunol; 2019 Dec; 30(8):817-823. PubMed ID: 31437325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness.
    Orgel K; Burk C; Smeekens J; Suber J; Hardy L; Guo R; Burks AW; Kulis M
    Clin Exp Allergy; 2019 Apr; 49(4):461-470. PubMed ID: 30383313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose oral immunotherapy for children with anaphylactic peanut allergy in Japan.
    Nagakura KI; Yanagida N; Sato S; Nishino M; Asaumi T; Ogura K; Ebisawa M
    Pediatr Allergy Immunol; 2018 Aug; 29(5):512-518. PubMed ID: 29603410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
    Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC
    Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy.
    Patil SU; Steinbrecher J; Calatroni A; Smith N; Ma A; Ruiter B; Virkud Y; Schneider M; Shreffler WG
    J Allergy Clin Immunol; 2019 Nov; 144(5):1310-1319.e4. PubMed ID: 31377342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective.
    Vickery BP; Berglund JP; Burk CM; Fine JP; Kim EH; Kim JI; Keet CA; Kulis M; Orgel KG; Guo R; Steele PH; Virkud YV; Ye P; Wright BL; Wood RA; Burks AW
    J Allergy Clin Immunol; 2017 Jan; 139(1):173-181.e8. PubMed ID: 27522159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision cut intestinal slices, a novel model of acute food allergic reactions.
    Hung L; Celik A; Yin X; Yu K; Berenjy A; Kothari A; Obernolte H; Upton JEM; Lindholm Bøgh K; Somers GR; Siddiqui I; Grealish M; Quereshy FA; Sewald K; Chiu PPL; Eiwegger T
    Allergy; 2023 Feb; 78(2):500-511. PubMed ID: 36377289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of a probiotic with peanut oral immunotherapy: A randomized trial.
    Tang ML; Ponsonby AL; Orsini F; Tey D; Robinson M; Su EL; Licciardi P; Burks W; Donath S
    J Allergy Clin Immunol; 2015 Mar; 135(3):737-44.e8. PubMed ID: 25592987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
    Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
    Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral immunotherapy induces IgG antibodies that act through FcγRIIb to suppress IgE-mediated hypersensitivity.
    Burton OT; Logsdon SL; Zhou JS; Medina-Tamayo J; Abdel-Gadir A; Noval Rivas M; Koleoglou KJ; Chatila TA; Schneider LC; Rachid R; Umetsu DT; Oettgen HC
    J Allergy Clin Immunol; 2014 Dec; 134(6):1310-1317.e6. PubMed ID: 25042981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Immunotherapy: An Overview.
    Todoric K; Merrill S
    Prim Care; 2023 Jun; 50(2):269-281. PubMed ID: 37105606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapy.
    Chen G; Shrock EL; Li MZ; Spergel JM; Nadeau KC; Pongracic JA; Umetsu DT; Rachid R; MacGinnitie AJ; Phipatanakul W; Schneider L; Oettgen HC; Elledge SJ
    Cell Rep Med; 2021 Oct; 2(10):100410. PubMed ID: 34755130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy.
    Pagovich OE; Wang B; Chiuchiolo MJ; Kaminsky SM; Sondhi D; Jose CL; Price CC; Brooks SF; Mezey JG; Crystal RG
    J Allergy Clin Immunol; 2016 Dec; 138(6):1652-1662.e7. PubMed ID: 27372563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.